Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.

Rifasutenizol is a new molecular entity specifically designed for the treatment of H. pylori infection. It possesses a synergistic dual mechanism of action with a low propensity for the development of antimicrobial resistance. Rifasutenizol exhibited potent activity against H. pylori clinical isolates collected from different regions in China and the United States, including those resistant to antibiotics currently used for the treatment of H. pylori infection. TenNor has completed a series of phase I/II clinical trials in China on rifasutenizol and received an IND, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The article published in Lancet ID reported the phase I/II clinical study results, including data from single ascending dose and food effects, multiple ascending dose, dose ranging and regimen development studies.

Lancet ID publishes original research that advocates change in or illuminates infectious disease clinical practice and informative reviews on any topic connected with infectious diseases and human health. The journal’s preference is to publish articles likely to influence clinical practice or thinking. The impact factor of the journal is 56.3, ranking first among 96 infectious disease journals in the world.

Link to the article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00003-3/abstract

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com